Transient Expression of Therapeutic Proteins via Electroporation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Transient gene expression (TGE) in bioreactors faces challenges such as low productivity, inconsistent product quality, and scalability issues, limiting its application to non-GLP preclinical studies and preventing widespread use in clinical development.
Innovation Solution
A method for high-yield and high-quality production of recombinant proteins in large-scale bioreactors involves culturing eukaryotic cells to high density and transiently transfecting them with a polynucleotide encoding the recombinant protein using electroporation, with optimized conditions including continuous ATF perfusion and post-transfection culturing parameters like temperature shift and addition of DMA and NaBu.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If transient gene expression is used to rapidly produce recombinant protein, then production timeline is shortened, but productivity (titer) is low
Solution Approach 1:
The patent applies parameter changes by optimizing multiple process variables including cell density (increased to >100×10^6 cells/mL), electroporation conditions (voltage, pulse duration, temperature), media composition, and culture conditions (temperature shift, perfusion rate). These parameter optimizations collectively increased protein titer from conventional low levels to >1 g/L while maintaining the rapid transient expression timeline advantage.
Solution Approach 2:
The patent implements preliminary action by pre-concentrating cells to high density before electroporation, pre-optimizing electroporation parameters based on cell state, and preparing optimized media formulations in advance. This preliminary preparation ensures maximum transfection efficiency and protein expression when the actual transient expression occurs, achieving high titer without extending the overall production timeline.
2Loss of time
If transient gene expression is used to accelerate production, then development timeline is reduced, but product quality consistency differs from clonal material
Solution Approach 1:
The patent uses parameter changes to control product quality by optimizing electroporation parameters (temperature, voltage, pulse duration) to ensure consistent cell membrane permeabilization, optimizing DNA-to-cell ratio for uniform transfection, and controlling culture parameters (pH, temperature, oxygen) during expression. These controlled parameter changes produce transient expression material with quality attributes matching clonal material.
Solution Approach 2:
The patent implements feedback control by monitoring cell density, viability, and expression levels during the transient expression process, then adjusting parameters such as perfusion rate, temperature, and media supplementation to maintain optimal conditions. This feedback ensures consistent product quality attributes including glycosylation, aggregation, and charge variants match those from clonal production.
3Adaptability or versatility
If transient gene expression is implemented, then scalability for clinical development is improved, but current limitations prevent widespread application
Solution Approach 1:
The patent achieves universality by developing a scalable transient expression platform that can produce clinical-grade material with quality attributes suitable for multiple downstream applications including preclinical studies, toxicological studies, formulation development, and clinical trials. The same optimized process produces material meeting GLP and GMP requirements, making the technology universally applicable across development stages.
Solution Approach 2:
The patent enables scalability through parameter changes including increasing bioreactor scale from small scale to large scale (1000L+), optimizing cell concentration and electroporation parameters for large volume processing, and adjusting perfusion and culture parameters for scaled-up systems. These parameter optimizations maintain high titer (>1 g/L) and product quality consistency across scales, enabling clinical development readiness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method achieves recombinant protein yields of up to 2 g/L and product quality comparable to clonal material, enabling scalable and efficient production suitable for clinical development.
Implementation Method 1
transiently transfecting the eukaryotic cells with a polynucleotide encoding the recombinant protein using electroporation
Data Source
AI summary
The present disclosure provide novel methods of large-scale production of recombinant proteins, e.g., therapeutic proteins such as antibodies, comprising concentrating an eukaryotic cell culture to a high density and transiently transfecting the eukaryotic cells with a polynucleotide encoding the recombinant protein using electroporation, e.g., flow electroporation. In some aspects, the culture is performed under perfusion conditions using, e.g., a tangential flow filtration method such as alternating tangential flow filtration. The proteins obtained using the disclosed methods are comparable to those produced using stable transfection. The methods disclosed herein can be used, for example, to accelerate therapeutic agent development, to reduce host cell toxicity, or for individualized therapeutics such as small scale manufacturing of treatments for rare or orphan diseases.